Brief: SOBI's Pozdeutinurad Meets Phase 3 Primary Endpoint In REDUCE-2
29/10/2026 07:18
BRIEF-SOBI's Pozdeutinurad Meets Phase 3 Primary Endpoint In REDUCE-2 Oct 29 (Reuters) - Swedish Orphan Biovitrum AB (publ) SOBIV.ST:
LATE-BREAKING PHASE 3 REDUCE-2 DATA SHOW CLINICALLY MEANINGFUL AND DURABLE SERUM URATE LOWERING WITH POZDEUTINURAD
PHASE 3 STUDY SHOWS STATISTICALLY SIGNIFICANT SERUM URATE REDUCTIONS THROUGH 12 MONTHS
POZDEUTINURAD DEMONSTRATES DURABLE SERUM URATE REDUCTIONS AND SAFETY COMPARABLE TO PLACEBO
REDUCE-2 STUDY MEETS PRIMARY ENDPOINT WITH SIGNIFICANT SERUM URATE REDUCTIONS AT MONTH 6
Further company coverage: SOBIV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Swedish Orphan Biovitrum AB (publ)
See all newsTop of the Street: SOBI, Sonova, BAT, Imperial Brands
SOBI slips after Ionis lowers Tryngolza sales forecast
Brief: Swedish Orphan Biovitrum Executive Sells, Buys Shares
Europe Research Roundup: Centrica, Fuchs, URW
Brief: Swedish Orphan Biovitrum Proposes Börje Ekholm As New Chair And Board Member At 2027 AGM